Eran Broshy's most recent trade in Theravance Biopharma Inc was a trade of 15,501 Ordinary Shares done at an average price of $20 . Disclosure was reported to the exchange on Nov. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Theravance Biopharma Inc | Eran Broshy | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 26 Nov 2025 | 15,501 | 44,703 (0%) | 0% | 20 | 310,020 | Ordinary Shares |
| Theravance Biopharma Inc | Eran Broshy | Director | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 26 Nov 2025 | 14,000 | 60,204 (0%) | 0% | 20 | 280,000 | Ordinary Shares |
| Theravance Biopharma Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2025 | 14,000 | 81,749 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Sale of securities on an exchange or to another person at price $ 17.00 per share. | 11 Nov 2025 | 15,500 | 60,204 (0%) | 0% | 17 | 263,500 | Ordinary Shares |
| Theravance Biopharma Inc | Eran Broshy | Director | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 11 Nov 2025 | 15,500 | 75,704 (0%) | 0% | 18.5 | 286,750 | Ordinary Shares |
| Theravance Biopharma Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2025 | 14,000 | 107,878 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Sale of securities on an exchange or to another person at price $ 18.50 per share. | 11 Nov 2025 | 14,000 | 60,204 (0%) | 0% | 18.5 | 259,000 | Ordinary Shares |
| Certara Inc | Eran Broshy | Director, Chairman | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 15,757 | 15,757 | - | - | Restricted Stock Units | |
| Certara Inc | Eran Broshy | Director, Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 34,951 | - | 0 | Common Stock | |
| Certara Inc | Eran Broshy | Director, Chairman | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2025 | 11,928 | 0 | - | - | Restricted Stock Units | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 24,258 | 24,258 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 May 2025 | 10,649 | 91,204 (0%) | 0% | 0 | Ordinary Shares | |
| Certara Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2024 | 11,928 | 11,928 | - | - | Restricted Stock Units | |
| Certara Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 23,023 | - | 0 | Common Stock | |
| Certara Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 8,663 | 0 | - | - | Restricted Stock Units | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 23,576 | 23,576 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 May 2024 | 10,537 | 80,555 (0%) | 0% | 0 | Ordinary Shares | |
| Certara Inc | Eran Broshy | Director | Purchase of securities on an exchange or from another person at price $ 15.80 per share. | 21 Aug 2023 | 4,807 | 14,360 | - | 15.8 | 75,951 | Common Stock |
| Certara Inc | Eran Broshy | Director | Purchase of securities on an exchange or from another person at price $ 16.10 per share. | 21 Aug 2023 | 193 | 9,553 | - | 16.1 | 3,107 | Common Stock |
| Certara Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,360 | 9,360 | - | 0 | Common Stock | |
| Certara Inc | Eran Broshy | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 May 2023 | 9,360 | 0 | - | - | Restricted Stock Units | |
| Certara Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2023 | 8,663 | 8,663 | - | - | Restricted Stock Units | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 22,044 | 22,044 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 9,132 | 70,018 (0%) | 0% | 0 | Ordinary Shares | |
| Certara Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2022 | 9,360 | 9,360 | - | - | Restricted Stock Units | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 28,000 | 28,000 | - | - | Share Option (Right to Buy) | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Apr 2022 | 9,852 | 60,886 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 9,828 | 51,034 (0%) | 0% | 0 | Ordinary Shares | |
| Theravance Biopharma Inc | Eran Broshy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Apr 2021 | 6,000 | 6,000 | - | - | Share Option (Right to Buy) |